GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 204 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 1.05 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $151,000 | +71.6% | 2,214 | -20.0% | 0.01% | +100.0% |
| Q2 2022 | $88,000 | -8.3% | 2,769 | +0.4% | 0.00% | +50.0% |
| Q1 2022 | $96,000 | +3.2% | 2,759 | -13.1% | 0.00% | 0.0% |
| Q4 2021 | $93,000 | +13.4% | 3,175 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $82,000 | -30.5% | 3,227 | -3.9% | 0.00% | 0.0% |
| Q2 2021 | $118,000 | -13.9% | 3,357 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $137,000 | -26.3% | 3,357 | -21.9% | 0.00% | -25.0% |
| Q4 2020 | $186,000 | -21.5% | 4,301 | 0.0% | 0.00% | -33.3% |
| Q3 2020 | $237,000 | -12.9% | 4,301 | 0.0% | 0.01% | -14.3% |
| Q2 2020 | $272,000 | +21.4% | 4,301 | -1.9% | 0.01% | +16.7% |
| Q1 2020 | $224,000 | -36.7% | 4,386 | -1.5% | 0.01% | -25.0% |
| Q4 2019 | $354,000 | +59.5% | 4,453 | -2.9% | 0.01% | +60.0% |
| Q3 2019 | $222,000 | -8.6% | 4,585 | -0.8% | 0.01% | 0.0% |
| Q2 2019 | $243,000 | -2.8% | 4,624 | -2.2% | 0.01% | -16.7% |
| Q1 2019 | $250,000 | – | 4,730 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |